| Overview |
| bs-10476R-APC-Cy7 |
| C5a anaphylatoxin Polyclonal Antibody, APC-Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| APC-Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human C5a anaphylatoxin |
| 678-751/1676 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 727 |
| P01031 |
| Secreted |
| Anaphylatoxin C5a; C5; Complement C5; Complement C5 precursor; Complement component 5; CPAMD4; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4; Complement C5 alpha chain; C5a anaphylatoxin; Complement C5 alpha' chain; CO5_HUMAN. |
| The protein encoded by this gene is the fifth component of complement, which plays an important role in inflammatory and cell killing processes. This protein is comprised of alpha and beta polypeptide chains that are linked by a disulfide bridge. An activation peptide, C5a, which is an anaphylatoxin that possesses potent spasmogenic and chemotactic activity, is derived from the alpha polypeptide via cleavage with a convertase. The C5b macromolecular cleavage product can form a complex with the C6 complement component, and this complex is the basis for formation of the membrane attack complex, which includes additional complement components. Mutations in this gene cause complement component 5 deficiency, a disease where patients show a propensity for severe recurrent infections. Defects in this gene have also been linked to a susceptibility to liver fibrosis and to rheumatoid arthritis. [provided by RefSeq, Jul 2008]. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz